| Literature DB >> 26227551 |
Chandrima Sinha1,2, Weiqiang Zhang2,3, Chang Suk Moon1, Marcelo Actis4, Sunitha Yarlagadda1, Kavisha Arora1, Koryse Woodroofe1, John P Clancy1, Songbai Lin1, Assem G Ziady1, Raymond Frizzell5, Naoaki Fujii4, Anjaparavanda P Naren6,7.
Abstract
Cystic fibrosis (CF) is a lethal genetic disease caused by the loss or dysfunction of the CF transmembrane conductance regulator (CFTR) channel. F508del is the most prevalent mutation of the CFTR gene and encodes a protein defective in folding and processing. VX-809 has been reported to facilitate the folding and trafficking of F508del-CFTR and augment its channel function. The mechanism of action of VX-809 has been poorly understood. In this study, we sought to answer a fundamental question underlying the mechanism of VX-809: does it bind CFTR directly in order to exert its action? We synthesized two VX-809 derivatives, ALK-809 and SUL-809, that possess an alkyne group and retain the rescue capacity of VX-809. By using Cu(I) -catalyzed click chemistry, we provide evidence that the VX-809 derivatives bind CFTR directly in vitro and in cells. Our findings will contribute to the elucidation of the mechanism of action of CFTR correctors and the design of more potent therapeutics to combat CF.Entities:
Keywords: CFTR correctors; VX-809; click chemistry; cystic fibrosis; protein expression
Mesh:
Substances:
Year: 2015 PMID: 26227551 PMCID: PMC4672727 DOI: 10.1002/cbic.201500123
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.164